

Supplementary Table S1. Clinicopathological characteristics according to total tumor size

	≤2 cm (n=19, 13.4%)	2–5 cm (n=51, 35.9%)	5–10 cm (n=52, 36.6%)	>10 cm (n=20, 14.1%)	p-value
Clinical findings					
Age ≥60 yr	10 (52.6)	29 (56.9)	21 (40.4)	13 (65.0)	.921
Sex (male/female)	16 (84.2)/3 (15.8)	40 (78.4)/11 (21.6)	35 (67.3)/17 (32.7)	19 (95.0)/1 (5.0)	.920
B-viral etiology	17 (89.5)	42 (82.4)	41 (78.8)	12 (60.0)	.028
Preoperative locoregional treatment	9 (47.4)	23 (45.1)	18 (34.6)	4 (20.0)	.038
Serum AFP level ≥1,000 ng/mL	2 (10.5)	9 (17.6)	18 (34.6)	7 (35.0)	.013
Serum PIVKA-II level ≥200 mAU/mL (n=120)	2/16 (12.5)	10/42 (23.8)	31/43 (72.1)	17/19 (89.5)	<.001
Pathological findings					
Gross type 2	9 (47.4)	26 (51.0)	24 (46.2)	15 (75.0)	.193
Necrosis (present)	3 (15.8)	21 (41.2)	16 (30.8)	9 (45.0)	.253
Extent of necrosis (%) (n=49)	30.0 (10.0-60.0)	70.0 (1.0-99.0)	65.0 (1.0-90.0)	40.0 (10.0-80.0)	.585
Edmondson-Steiner grade III or IV	10 (52.6)	36 (70.6)	39 (75.0)	15 (75.0)	.120
Microvascular invasion (present)	2 (10.5)	18 (35.3)	26 (50.0)	7 (35.0)	.038
Major vessel invasion (present)	1 (5.3)	6 (11.8)	8 (15.4)	5 (25.0)	.071
Underlying cirrhosis (present)	15 (78.9)	40 (78.4)	33 (63.5)	9 (45.0)	.005
pT category					<.001
pT1a	18 (94.7)	0	0	0	
pT1b	0	31 (60.8)	21 (40.4)	10 (50.0)	
pT2	0	16 (31.4)	20 (38.5)	6 (30.0)	
pT4	1 (5.3)	4 (7.8)	11 (21.2)	4 (20.0)	
CK19 positivity (n=112)	2/13 (15.4)	4/40 (10.0)	3/41 (7.3)	1/18 (5.6)	.316

Values are presented as median (range) or number (%).

AFP, α -fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; CK19, cytokeratin 19.